AI assistant
Sending…
ATOSSA THERAPEUTICS, INC. — Director's Dealing 2017
Nov 16, 2017
34113_dirs_2017-11-16_c419c14b-b01e-442c-9b10-ba004c3f7b19.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ATOSSA GENETICS INC (ATOS)
CIK: 0001488039
Period of Report: 2017-11-15
Reporting Person: Guse Kyle (CFO, Gen Counsel and Secretary)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-11-15 | Common Stock | P | 8600 | $0.337 | Acquired | 8600 | Direct |
| 2017-11-15 | Common Stock | P | 1400 | $0.3365 | Acquired | 10000 | Direct |
More from ATOSSA THERAPEUTICS, INC.
Regulatory Filings
2026
May 8
Interim / Quarterly Report
2026
May 8
Regulatory Filings
2026
May 8
Regulatory Filings
2026
Apr 16
Director's Dealing
2026
Mar 31
Annual Report
2026
Mar 25
Regulatory Filings
2026
Mar 20
Regulatory Filings
2026
Feb 20
Regulatory Filings
2026
Feb 17
Regulatory Filings
2026
Feb 11